EE232 A Real-World (RW) Comparison of Healthcare Expenditures in Patients Prescribed Aripiprazole Tablet with Sensor (AS) and Patients Prescribed Aripiprazole Alone [Aripiprazole without Sensor (ARI)] in the US

Abstract

Indicated for treatment of adults with bipolar I disorder (BP1), schizophrenia (SCZ) and major depressive disorder (MDD), AS is a drug-device system comprised of aripiprazole tablets embedded with an Ingestible Event Marker tracking drug ingestion, mood, rest and physical activity. This study compares healthcare expenditures in patients prescribed AS versus a matched ari only cohort.